Lessons from the Established Status Epilepticus Treatment Trial

摘要: Abstract Convulsive status epilepticus (SE) is a relatively common emergency condition affecting individuals of all ages. The primary goal treatment prompt termination seizures. Where first-line with benzodiazepine has failed to achieve this, known as established SE (ESE), there uncertainty about which agent use next. Established Status Epilepticus Treatment Trial (ESETT) 3-arm (valproate (VPA), fosphenytoin (FOS), levetiracetam (LEV)), phase III, double-blind randomized comparative effectiveness study in patients aged 2 years and above convulsive SE. Enrollment was completed January 2019, the results are expected later this year. We discuss lessons learnt during conduct relation following: ethical considerations; trial design practical implementation settings, including pediatric adult populations; quality assurance; outcome determination where treating clinicians may lack specialist expertise. consider that ESETT already informing both clinical practice future design. This article part Special Issue “Proceedings 7th London-Innsbruck Colloquium on Acute Seizures"